問卷

TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Orthopedics

更新時間:2023-09-19

陳春忠Chen, Chun-Chung
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月
  • D6407@mail.cmuh.org.tw

篩選

List

6Cases

2019-11-01 - 2024-05-13

Phase II

Completed
A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    Erdafitinib

Participate Sites
13Sites

Not yet recruiting2Sites

Recruiting5Sites

Terminated6Sites

2024-05-01 - 2027-06-30

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2019-03-01 - 2026-12-31

Phase II

Active
A Phase II, Randomized, Open-Label, Parallel-Group Autologous Dendritic Cell Vaccination as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
  • Condition/Disease

    Glioblastoma Multiforme (GBM)

  • Test Drug

    ADCV01

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2019-06-01 - 2023-05-31

Phase II

Completed
Stopping haemorrhage with Tranexamic acid for hyperacute Onset Presentation including Mobile Stroke Units
  • Condition/Disease

    Intracerebral haemorrhage (ICH)

  • Test Drug

    Tranexamic acid

Participate Sites
3Sites

Recruiting3Sites

2016-06-13 - 2020-12-31

Phase II

Completed
STOP-AUST: The Spot sign and Tranexamic acid On Preventing ICH growth – AUStralasia Trial
  • Condition/Disease

    Intracerebral haemorrhage (ICH)

  • Test Drug

    Tranexamic acid

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

2015-05-01 - 2020-06-11

Phase II

ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group
  • Condition/Disease

    Glioblastoma Multiforme (GBM)

  • Test Drug

    ABT-414

Participate Sites
5Sites

Terminated5Sites